Overcoming lysosomal barrier via V-ATPase: an exosome-based co-delivery platform for combined chemo/RNAi therapy against breast cancer - PubMed
7 hours ago
- #breast cancer therapy
- #lysosomal escape
- #exosome delivery
- Developed a nano-delivery system called CEL-TPP@siSurvivin/TDNP NPs for combined chemo/gene therapy against breast cancer.
- The system uses triphenylphosphine-modified celastrol and siSurvivin encapsulated in turmeric-derived nanoparticles to enhance tumor cell apoptosis.
- It overcomes lysosomal entrapment by upregulating V-ATPase subunits, leading to lysosomal hyperacidification and facilitating nanoparticle escape.
- In vivo studies in a 4T1 murine breast cancer model showed potent antitumor efficacy and good biosafety.
- Presents a novel strategy to address lysosomal escape in nanomedicine for efficient combined therapy.